Related Experiment Video
Updated: Aug 14, 2026
09:40
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Gene expression profiles associated with treatment response in oligodendrogliomas
Pim J French1, Sigrid M A Swagemakers, Jord H A Nagel
1Department of Neurology, Cancer Genomics Center, Erasmus Medical Center, Rotterdam, the Netherlands. p.french@erasmusmc.nl
Cancer Research
|December 17, 2005
Summary
Gene expression profiling identifies oligodendrogliomas sensitive to chemotherapy, independent of chromosomal aberrations. This approach can predict patient prognosis and treatment response in brain tumors.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genetics
Background:
- Oligodendrogliomas are brain tumors often responsive to chemotherapy.
- Loss of heterozygosity on chromosomes 1p and 19q is linked to treatment response.
Purpose of the Study:
- To identify chemosensitive oligodendrogliomas using gene expression profiling.
- To correlate gene expression with chromosomal aberrations (1p/19q loss).
- To link gene expression to treatment response and patient survival.
Main Methods:
- Utilized expression profiling of oligodendroglioma tumors.
- Correlated gene expression data with 1p/19q chromosomal status.
- Analyzed gene expression in relation to chemotherapy response and patient survival data.
Main Results:
- Identified hundreds of differentially expressed probe sets associated with 1p/19q loss.
- Discovered 16 differentially expressed probe sets linked to chemotherapy response, independent of chromosomal aberrations.
- Found 103 differentially expressed probe sets correlating with patient survival.
Conclusions:
- Gene expression profiling offers an alternative to 1p/19q status for identifying chemosensitive oligodendrogliomas.
- Differentially expressed genes are crucial for predicting patient prognosis.
- This study pioneers the correlation of gene expression with chromosomal aberrations and clinical outcomes in oligodendrogliomas.
